{
 "metadata": {
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.3-final"
  },
  "orig_nbformat": 2,
  "kernelspec": {
   "name": "python3",
   "display_name": "Python 3.8.3 64-bit ('anaconda3': virtualenv)",
   "metadata": {
    "interpreter": {
     "hash": "9a7655c32bbe1d4ad574c83fc6ca14ff729bdb80a0e07c51d84f684469ab9ed6"
    }
   }
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2,
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "from clin_class import *\n",
    "import pandas as pd\n",
    "ct = ClinTrials()\n",
    "# Ignore fields list includes too many lists, max limit is 20 fields\n",
    "fields = ['BriefTitle','CompletionDate','InterventionName','InterventionType','IsFDARegulatedDevice','IsFDARegulatedDrug','LeadSponsorName','LastUpdateSubmitDate',\n",
    "'LocationCountry','LocationFacility','LocationState','MaximumAge','MinimumAge','NCTId','OrgFullName','EnrollmentCount','EligibilityCriteria','PrimaryCompletionDate','OutcomeAnalysisCILowerLimit','OutcomeAnalysisCILowerLimitComment','OutcomeAnalysisCINumSides','OutcomeAnalysisCIPctValue','OutcomeAnalysisCIUpperLimit','OutcomeAnalysisPValue','OutcomeMeasureAnticipatedPostingDate','OtherOutcomeDescription','OtherOutcomeMeasure','OtherOutcomeTimeFrame','OtherEventStatsNumAffected','OtherEventStatsNumAtRisk','OtherEventTerm']\n",
    "\n",
    "f_ = ['OfficialTitle','OverallOfficialName','EnrollmentCount','PrimaryOutcomeMeasure','PrimaryOutcomeTimeFrame','SecondaryOutcomeMeasure','SecondaryOutcomeTimeFrame','EligibilityCriteria','StudyPopulation','StartDate','PrimaryCompletionDate','ReferenceCitation']\n",
    "d_ = ct.get_study_fields('covid',f_,fmt=\"json\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "output_type": "execute_result",
     "data": {
      "text/plain": [
       " for the clinical picture (eg adult patients sedated and curarized for acute respiratory failure and consequent mechanical ventilation), the patient's consent will be assumed until the contrary will be manifested.\\n\\nExclusion Criteria:\\n\\n-\"],\n",
       "    'StudyPopulation': ['The study involves the enrollment of ≥ 400 consecutive hospitalized patients diagnosed with COVID-19, aged> 18 years.'],\n",
       "    'StartDate': ['March 25, 2020'],\n",
       "    'PrimaryCompletionDate': ['April 25, 2021'],\n",
       "    'ReferenceCitation': []},\n",
       "   {'Rank': 44,\n",
       "    'OfficialTitle': ['Gastrointestinal Symptoms of SARS-CoV-2 Infection: a Prospective Multicentre Study'],\n",
       "    'OverallOfficialName': ['Giovanni Barbara, MD'],\n",
       "    'EnrollmentCount': ['2000'],\n",
       "    'PrimaryOutcomeMeasure': ['Prevalence of gastrointestinal symptoms in patients admitted to hospital for COVID19 disease as assessed by GSRS questionnaire',\n",
       "     'Prognosis of gastrointestinal symptoms in patients admitted to hospital for COVID19 disease'],\n",
       "    'PrimaryOutcomeTimeFrame': ['one month', 'one month'],\n",
       "    'SecondaryOutcomeMeasure': ['Long term consequences of COVID-19 on gastrointestinal symptoms on the development of post-infection (PI) irritable bowel syndrome (IBS).',\n",
       "     'long term consequences of COVID-19 on gastrointestinal symptoms on the development of post-infection (PI) dyspepsia.',\n",
       "     'Identification of risk factors for post-infection gastrointestinal symptom development.'],\n",
       "    'SecondaryOutcomeTimeFrame': ['12 months', '12 months', '12 months'],\n",
       "    'EligibilityCriteria': ['Inclusion Criteria:\\n\\nSigned informed consent\\nAge ≥18 years and ≤85 years\\nConsecutive COVID19 confirmed patients (COVID +ve) (case group)\\nConsecutive hospitalized COVID19 negative patients (COVID -ve) (control group)\\nAbility to conform to study protocol\\n\\nExclusion Criteria:\\n\\nPatients under mechanical ventilation\\nPatients unable to report required data\\nCurrent diagnosis of cancer'],\n",
       "    'StudyPopulation': ['The study cohort will be composed by consecutively enrolled COVID19 confirmed inpatients (case group) and COVID19 negative patients hospitalized for other reasons (controls group) referred to the participants centres from May, 1 2020. From the beginning of the study (first patient enrolled in the centre), the enrolment will last for 1 month.'],\n",
       "    'StartDate': ['May 1, 2020'],\n",
       "    'PrimaryCompletionDate': ['September 30, 2020'],\n",
       "    'ReferenceCitation': []},\n",
       "   {'Rank': 45,\n",
       "    'OfficialTitle': ['Phase II Clinical Trial to Explore the Efficacy of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With Severe Pulmonary Involvement by COVID-19'],\n",
       "    'OverallOfficialName': ['Luis Madero, MD'],\n",
       "    'EnrollmentCount': ['106'],\n",
       "    'PrimaryOutcomeMeasure': ['Mortality due to lung involvement due to SARS-CoV-2 virus infection at 28 days of treatment'],\n",
       "    'PrimaryOutcomeTimeFrame': ['28 days'],\n",
       "    'SecondaryOutcomeMeasure': ['Mortality due to lung involvement due to SARS-CoV-2 virus infection at 14 days of treatment',\n",
       "     'Mortality from any cause at 28 days',\n",
       "     'Days without mechanical respirator and without vasopressor treatment for 28 days',\n",
       "     'Patients alive without mechanical ventilation and without vasopressors on day 28',\n",
       "     'Patients alive and without mechanical ventilation on day 14',\n",
       "     'Patients alive and without mechanical ventilation on day 28',\n",
       "     'Patients alive and without vasopressors on day 28',\n",
       "     'Days without vasopressors for 28 days',\n",
       "     'Patients cured at 15 days',\n",
       "     'Incidence of Treatment-Emergent Adverse Events'],\n",
       "    'SecondaryOutcomeTimeFrame': ['14 days',\n",
       "     '28 days',\n",
       "     '28 days',\n",
       "     '28 days',\n",
       "     '14 days',\n",
       "     '28 days',\n",
       "     '28 days',\n",
       "     '28 days',\n",
       "     '15 days',\n",
       "     '1 year'],\n",
       "    'EligibilityCriteria': ['Inclusion Criteria:\\n\\nPatients aged between 40 and 80 years\\nBody weight between 50 kg and 100 kg\\nPCR diagnosis of SARS-CoV-2 virus infection\\n\\nClinical diagnosis of severe lung involvement associated with SARSCoV- 2 virus infection according to the criteria of the National Health Commission of China, that is, patients who meet at least one of the following criteria:\\n\\nRespiratory distress with ≥ 30 breaths per minute; or\\nOxygen saturation ≤ 93% at baseline; or\\nPartial arterial oxygen pressure (PaO2) / Fraction of inspiration of O2 (FiO2) ≤300mmHg. (PaO2 / FiO2 is accepted based on SatO2). Patients who do not require respiratory support, or who require noninvasive respiratory support (conventional, high-flow oxygen therapy, or non-invasive mechanical ventilation) are considered eligible.\\nPatients who are already receiving the standard medical treatment available for severe lung involvement associated with SARS-CoV-2 virus infection or any of the standard treatments are contraindicated in the patient and cannot be used and it is necessary to consider other alternatives.\\nWomen who are surgically sterile or postmenopausal or women of childbearing potential with negative urine or serum pregnancy test or men willing to use condoms for the entire duration of the study or for three months after the last dose of the investigational drug, whichever is later, or have a partner who is using a contraceptive method with high efficacy, such as described above.\\nSigned informed consent.\\n\\nExclusion Criteria:\\n\\nClinical diagnosis of critically serious lung involvement associated with SARS-CoV-2 virus infection according to the criteria of the National Health Commission of China, that is, patients who meet any of the following criteria:\\n\\nRespiratory failure requiring invasive mechanical ventilation; or\\nShock; or\\nCombination with failure of another organ; need for ICU admission for monitoring / treatment.\\nPatients who are expected to develop rapidly fatal disease within 72 hours of enrollment.\\nInability to maintain a mean arterial pressure > 50 mmHg before selection despite the presence of vasopressors and intravenous fluids.\\nPatients requiring treatment with vasopressors (dopamine > 5 mg / kg / min or any dose of epinephrine, norepinephrine, phenylephrine, or vasopressin) for at least 2 hours to maintain systolic blood pressure (SBP) > 90 mmHg (or mean blood pressure [MBP] > 70 mmHg) after adequate fluid administration.\\nPatients who are not expected to live more than 3 months due to other medical illnesses, such as neoplasia or other terminal illnesses.\\nPatients with primary or metastatic lung cancer or with chemotherapy scheduled for the next 90 days.\\nPatients with a known primary immunodeficiency disorder or with acquired immunodeficiency syndrome (HIV infection) with a CD4 count <200 cells / mm3 or who do not have an undetectable viral load (<200 copies).\\nPatients receiving immunosuppressive therapy (including chronic treatment with any alpha antitumor necrosis factor [TNFa]) or corticosteroid therapy.\\nGranulocytopenia, not due to sepsis, evidenced by an absolute neutrophil count <500 per μL.\\nHematologic or lympho-reticular malignancies, unless in remission.\\nPatients who have received a stem cell, organ, or bone marrow transplant in the last 6 months.\\nPatients in current treatment with a biological product (eg, antibodies, cell therapy) or with plasmapheresis in the last 8 weeks.\\nPatients who are currently receiving or have received another investigational drug in the 90 days prior to study initiation (or 5 halflives of the investigational compound, whichever is longer).\\nKnown allergies or hypersensitivity to antibiotics and/or any component of the investigational product.\\nPatients with known severe liver function impairment.\\nPatients with known severe kidney function impairment.\\nPatients admitted in the previous 15 days for causes other than SARS-CoV-2 virus infection.\\nDiseases other than SARS-CoV-2 virus infection leading to New York Heart Association class IV status.\\nTerminal neuromuscular disorders that alter the gradual withdrawal of the ventilator (eg, amyotrophic lateral sclerosis).\\nPatients with complete tetraplegia (traumatic or otherwise).\\nDementia-Alzheimer and another situation in which is considered patient can not understand what is explaining, can not read or does not understand the language.'],\n",
       "    'StudyPopulation': [],\n",
       "    'StartDate': ['May 7, 2020'],\n",
       "    'PrimaryCompletionDate': ['July 31, 2020'],\n",
       "    'ReferenceCitation': []},\n",
       "   {'Rank': 46,\n",
       "    'OfficialTitle': ['A Stepped-wedge Cluster Randomized Trial to Assess the Effectiveness of the Use of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac'],\n",
       "    'OverallOfficialName': ['Ricardo Palacios, MD, PhD'],\n",
       "    'EnrollmentCount': ['27711'],\n",
       "    'PrimaryOutcomeMeasure': ['Incidence of COVID-19 cases after two-doses immunization schedule in clusters in the first quarter of study'],\n",
       "    'PrimaryOutcomeTimeFrame': ['Thirteen weeks after the beginning of study vaccination'],\n",
       "    'SecondaryOutcomeMeasure': ['Incidence of COVID-19 cases after two-doses immunization schedule in clusters up to one year of study',\n",
       "     'Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to immunization status',\n",
       "     'Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to pre-existing SARS-CoV-2 antibodies',\n",
       "     'Incidence of COVID-19 cases after two-doses immunization schedule in clusters according to immunization coverage',\n",
       "     'Incidence of hospitalization and death due to COVID-19 after two-doses immunization schedule in clusters',\n",
       "     'Change in average number of reported COVID-19 cases in the study area in comparison to other neighboring cities',\n",
       "     'Medically-attended adverse reactions to the study vaccine',\n",
       "     'Frequency of severe COVID-19 cases',\n",
       "     'Frequency of adverse events of special interest after immunization',\n",
       "     'Acceptability of the study vaccine',\n",
       "     'Adherence to vaccination schedule'],\n",
       "    'SecondaryOutcomeTimeFrame': ['One year after the beginning of study vaccination',\n",
       "     'One year after the beginning of study vaccination',\n",
       "     'One year after the beginning of study vaccination',\n",
       "     'One year after the beginning of study vaccination',\n",
       "     'One year after the beginning of study vaccination',\n",
       "     'One year after the beginning of study vaccination',\n",
       "     'One week after each vaccination',\n",
       "     'From first vaccination up to one year after first dose',\n",
       "     'From first vaccination up to one year after first dose',\n",
       "     'Two weeks after the beginning of study vaccination of the corresponding cluster',\n",
       "     'Six weeks after the beginning of study vaccination of the corresponding cluster'],\n",
       "    'EligibilityCriteria': [\"Inclusion Criteria:\\n\\nAdults 18 years of age or older;\\nResident in the study area;\\nShow voluntary intention to participate in the study, documented by the informed consent form signed by participant.\\n\\nExclusion Criteria:\\n\\nFor females: Pregnancy (confirmed by positive beta-hCG test), breastfeeding or intent to engage in sexual relations with reproductive intent without use of birth control methods in the three months following vaccination;\\nEvidence of uncontrolled neurological, cardiac, pulmonary, hepatic or renal disease, according to anamnesis or physical examination. Significant changes in treatment or hospitalizations due to worsening of the condition in the last three months are indicators of uncontrolled disease;\\nDiseases with impaired immune system including: neoplasms (except basal cell carcinoma), congenital or acquired immunodeficiencies and autoimmune diseases not controlled according to anamnesis or physical examination. Significant changes in treatment or hospitalizations due to worsening of the condition in the last three months are indicators of uncontrolled disease;\\nBehavioral, cognitive or psychiatric disease that, in the opinion of the principal investigator or his or her representative physician, affects the participant's ability to understand and cooperate with all study protocol requirements;\\nAny alcohol or drug abuse over the 12 months prior to enrollment in the study that has caused medical, professional or family problems, indicated by clinical history;\\nHistory of severe allergic reactions or anaphylaxis to the study vaccine or to components thereof;\\nHistory of asplenia;\\nParticipation in another clinical trial with an investigational product in the six months prior to enrollment in the study or planned participation in another clinical trial within the two years following enrollment;\\nPrevious participation in a study to evaluate a COVID-19 vaccine or prior exposure to a COVID-19 vaccine;\\nUse of immunosuppressant therapy regimens within the six months prior to enrollment in the study for planned use within the two years following enrollment. Immunosuppressant therapy regimens include: antineoplastic chemotherapy, radiation therapy and immunosuppressants to induce transplant tolerance, among others.\\nUse of immunosuppressive doses of corticosteroids within the three months prior to the enrollment in the study and planned use of immunosuppressive doses of corticoids within the three months following enrollment in the study. Immunosuppressive doses of corticosteroids will be considered the equivalent prednisone 20 mg/day for adults, for longer than one week. Continued use of topical or nasal corticosteroids is not considered an immunosuppressant;\\nReceived blood products (transfusions or immunoglobulins) within the three months prior to enrollment in the study, or planned administration of blood products or immunoglobulins within the two years following enrollment in the study;\\nSuspected or confirmed fever within the 72 hours prior to vaccination or axillary temperature greater than 37.8 °C* on the day of vaccination (enrollment may be postponed until participant has gone 72 hours without fever);\\nPossible or confirmed case of COVID-19 on the day of vaccination (vaccination can be postponed until the participant completes 72 hours without symptoms or the diagnosis is ruled out);\\nReceived live attenuated virus vaccine or inactivated vaccine within the 28 days or 14 days, respectively, prior to enrollment in the study, or immunization planned within the 28 days after enrollment in the study;\\nHistory of bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture\\nAny other condition that, in the opinion of the principal investigator or his/her representative physician, could put the safety/rights of potential participants at risk or prevent them from complying with this protocol.\"],\n",
       "    'StudyPopulation': [],\n",
       "    'StartDate': ['February 7, 2021'],\n",
       "    'PrimaryCompletionDate': ['May 2021'],\n",
       "    'ReferenceCitation': []},\n",
       "   {'Rank': 47,\n",
       "    'OfficialTitle': ['Rapid Diagnostic Test for COVID-19 Based on Antibody Detection'],\n",
       "    'OverallOfficialName': [],\n",
       "    'EnrollmentCount': ['3500'],\n",
       "    'PrimaryOutcomeMeasure': ['IgG anti-COVID-19',\n",
       "     'IgM anti-COVID-19',\n",
       "     'IgA anti-COVID-19'],\n",
       "    'PrimaryOutcomeTimeFrame': ['From May to July',\n",
       "     'From May to July',\n",
       "     'From May to July'],\n",
       "    'SecondaryOutcomeMeasure': ['Time of onset symptoms',\n",
       "     'COVID-19 PCR results',\n",
       "     'Radiological studies'],\n",
       "    'SecondaryOutcomeTimeFrame': ['From May to July',\n",
       "     'From May to July',\n",
       "     'From May to July'],\n",
       "    'EligibilityCriteria': ['Inclusion Criteria:\\n\\nProfessional from Parc Taulí University Hospital\\nPatients with clinical, radiological and/or PCR COVID-19 positive\\n\\nExclusion Criteria:\\n\\nPatients or professionals who do not sign informed consent'],\n",
       "    'StudyPopulation': ['Patients with COVID-19 infection Professionals of an University Hospital'],\n",
       "    'StartDate': ['June 22, 2020'],\n",
       "    'PrimaryCompletionDate': ['July 31, 2020'],\n",
       "    'ReferenceCitation': []},\n",
       "   {'Rank': 48,\n",
       "    'OfficialTitle': ['Prospective Study on the Impact of COVID-19 on the Equilibrium of Hereditary Metabolic Disease (MHM) in Patients With or Who Have Contracted COVID-19'],\n",
       "    'OverallOfficialName': ['Claire Douillard, MD'],\n",
       "    'EnrollmentCount': ['77'],\n",
       "    'PrimaryOutcomeMeasure': ['Frequency of MHM imbalance triggered by COVID-19'],\n",
       "    'PrimaryOutcomeTimeFrame': ['at 8 weeks'],\n",
       "    'SecondaryOutcomeMeasure': [\"Number of COVID-19 patients in Gaucher's disease\",\n",
       "     'Number of COVID-19 patients in Urea Cycle Disorder',\n",
       "     'Severity of COVID-19 infection'],\n",
       "    'SecondaryOutcomeTimeFrame': ['at 24 months',\n",
       "     'at 24 months',\n",
       "     'at 24 months'],\n",
       "    'EligibilityCriteria': ['Inclusion Criteria:\\n\\nChild or adult patient with a diagnosis of IMD\\nSymptomatic or asymptomatic patient tested positive for COVID-19 (PCR and/or serology)\\nSymptomatic patient non tested but with strong clinical suspicion for COVID-19\\nPatient affiliated with the health insurance\\n\\nExclusion Criteria:\\n\\ninability to receive informed information\\nPersons deprived of liberty'],\n",
       "    'StudyPopulation': ['IMD patients followed in reference centers for IMD in France. children and adult patients with MHM who have been infected with COVID-19 (tested positive or considered positive for COVID-19). Asymptomatic MHM patients tested positive for COVID 19 (contact case, for example) will also be studied.'],\n",
       "    'StartDate': ['January 2021'],\n",
       "    'PrimaryCompletionDate': ['January 2023'],\n",
       "    'ReferenceCitation': []},\n",
       "   {'Rank': 49,\n",
       "    'OfficialTitle': ['MURDOCK Cabarrus County COVID-19 Prevalence and Immunity (C3PI) Study'],\n",
       "    'OverallOfficialName': ['Kristin Newby, MD'],\n",
       "    'EnrollmentCount': ['500'],\n",
       "    'PrimaryOutcomeMeasure': ['Estimate the prevalence of COVID-19 infection based on responses to questionnaire items on symptoms and practices using a biweekly electronic survey.',\n",
       "     'Assess perceptions, concerns, and practices related to the COVID-19 pandemic and mitigation strategies',\n",
       "     'Estimate of the prevalence of active infection in Cabarrus County.',\n",
       "     'Estimate of the prevalence of exposure and potential immunity to COVID-19.'],\n",
       "    'PrimaryOutcomeTimeFrame': ['6 months',\n",
       "     '6 months',\n",
       "     '6 months',\n",
       "     '6 months'],\n",
       "    'SecondaryOutcomeMeasure': [],\n",
       "    'SecondaryOutcomeTimeFrame': [],\n",
       "    'EligibilityCriteria': ['Inclusion Criteria:\\n\\nMURDOCK Study participants ( Pro00011196) currently residing in North Carolina who have a valid email address on file.\\n\\nExclusion Criteria:\\n\\nMURDOCK Study participants ( Pro00011196) currently not residing in North Carolina\\nMURDOCK Study participants without a valid email address on file.'],\n",
       "    'StudyPopulation': ['ALL active MURDOCK study participants who currently reside in North Carolina and have a valid email address. The demographics of the MURDOCK study cohort are representative of the population in Cabarrus County and North Carolina.'],\n",
       "    'StartDate': ['June 9, 2020'],\n",
       "    'PrimaryCompletionDate': ['June 30, 2021'],\n",
       "    'ReferenceCitation': []},\n",
       "   {'Rank': 50,\n",
       "    'OfficialTitle': ['Impact of the Restrictive Visiting Policy During the Covid-19 Pandemic on Anxiety, Depression and Post-traumatic Stress Disorder for Relatives of ICU Patients'],\n",
       "    'OverallOfficialName': [],\n",
       "    'EnrollmentCount': ['480'],\n",
       "    'PrimaryOutcomeMeasure': ['Anxiety', 'Depression'],\n",
       "    'PrimaryOutcomeTimeFrame': ['Between 3 and 6 months',\n",
       "     'Between 3 and 6 months'],\n",
       "    'SecondaryOutcomeMeasure': ['post-traumatic stress disorder'],\n",
       "    'SecondaryOutcomeTimeFrame': ['between 3 and 6 months'],\n",
       "    'EligibilityCriteria': ['Inclusion Criteria:\\n\\nRelative of patient who was admitted in ICU and treated with invasive mechanical ventilation administration during 24hours at least.\\n\\nExclusion Criteria:\\n\\nRelative who declines the enrollment'],\n",
       "    'StudyPopulation': ['Relative of patient who was admitted in ICU and treated with mechanical ventilation or non-invasive ventilation or high flow oxygen or amine administration during 24hours at least.'],\n",
       "    'StartDate': ['June 22, 2020'],\n",
       "    'PrimaryCompletionDate': ['October 22, 2021'],\n",
       "    'ReferenceCitation': []}]}}"
      ]
     },
     "metadata": {},
     "execution_count": 8
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ]
}